
Privacy notice | Accessibility statement | Terms and conditions | Login | Contact |
UK data driving real-world evidence
Bibliography
Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 5 February 2021) and papers are listed below and in the PDF below.
If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.
Download:
(PDF, 3MB, 220 pages)This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website.
“Use of beta-blockers and risk of fractures”, Jama, vol. 292, pp. 1326-32, 2004.
, “Discontinuation and switching of therapy after initiation of lipid-lowering drugs: the effects of comorbidities and patient characteristics”, Br J Clin Pharmacol, vol. 56, pp. 84-91, 2003.
, “Lipid-lowering drugs and the risk of depression and suicidal behavior”, Arch Intern Med, vol. 163, pp. 1926-32, 2003.
, “Validity of the general practice research database”, Pharmacotherapy, vol. 23, pp. 686-9, 2003.
, “Who receives lipid-lowering drugs: the effects of comorbidities and patient characteristics on treatment initiation”, Br J Clin Pharmacol, vol. 55, pp. 288-98, 2003.
, “Itraconazole and fluconazole and certain rare, serious adverse events”, Pharmacotherapy, vol. 22, pp. 697-700, 2002.
, “Statins and the risk of idiopathic venous thromboembolism”, Br J Clin Pharmacol, vol. 53, pp. 101-5, 2002.
, “Live attenuated polio vaccine and the risk of intussusception”, Br J Clin Pharmacol, vol. 52, pp. 451-3, 2001.
, “The risk of cataract among users of inhaled steroids”, Epidemiology, vol. 12, pp. 229-34, 2001.
, “Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer”, Arch Intern Med, vol. 160, pp. 349-53, 2000.
, “Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide”, Arch Dermatol, vol. 136, pp. 1231-6, 2000.
, “The risk of gastrointestinal bleed, myocardial infarction, and newly diagnosed hypertension in users of meloxicam, diclofenac, naproxen, and piroxicam”, Pharmacotherapy, vol. 20, pp. 741-4, 2000.
, “Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis”, Bmj, vol. 321, pp. 1190-5, 2000.
, “Statins and the risk of dementia”, Lancet, vol. 356, pp. 1627-31, 2000.
, “Antibiotics and risk of subsequent first-time acute myocardial infarction”, Jama, vol. 281, pp. 427-31, 1999.
, “Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents”, Diabetes Care, vol. 22, pp. 2067-71, 1999.
, “Risk of idiopathic cerebral haemorrhage in women on oral contraceptives with differing progestagen components”, Lancet, vol. 354, pp. 302-3, 1999.
, “The risk of venous thromboembolism in users of postcoital contraceptive pills”, Contraception, vol. 59, pp. 79-83, 1999.
, “Acute respiratory-tract infections and risk of first-time acute myocardial infarction”, Lancet, vol. 351, pp. 1467-71, 1998.
, “A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation”, N Engl J Med, vol. 339, pp. 719-24, 1998.
, “Pregnancies and terminations after 1995 warning about third-generation oral contraceptives”, Lancet, vol. 351, pp. 1404-5, 1998.
, “A study of the relation of exposure to quinolones and suicidal behaviour”, Br J Clin Pharmacol, vol. 45, pp. 77-81, 1998.
, “Anticonvulsants and congenital malformations”, Pharmacotherapy, vol. 17, pp. 561-4, 1997.
, “Antidepressants and suicide”, Bmj, vol. 310, pp. 215-8, 1995.
, “Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components”, Lancet, vol. 346, pp. 1589-93, 1995.
, “A follow-up safety study of ciprofloxacin users”, Pharmacotherapy, vol. 13, pp. 461-4, 1993.
, “Nonsteroidal antiinflammatory drugs and certain rare, serious adverse events: a cohort study”, Pharmacotherapy, vol. 13, pp. 212-7, 1993.
, “Antidepressants and convulsions”, J Clin Psychopharmacol, vol. 12, pp. 241-5, 1992.
, “Liver disease associated with diclofenac, naproxen, and piroxicam”, Pharmacotherapy, vol. 12, pp. 207-12, 1992.
, “NSAIDs, quinolones and convulsions: An epidemiologic approach”, vol. 6, pp. 119-128, 1992.
, “Urinary tract infections and estrogen use in older women”, J Am Geriatr Soc, vol. 40, pp. 817-20, 1992.
, “Validation of information recorded on general practitioner based computerised data resource in the United Kingdom”, Bmj, vol. 302, pp. 766-8, 1991.
, “A comparison of the risk of hypoglycemia between users of human and animal insulins. 1. Experience in the United Kingdom”, Pharmacotherapy, vol. 10, pp. 395-7, 1990.
,